Fulzerasib

氟泽雷塞

Report date: 2026/03/26 20:00:17
NME

Base Information

Drug NameFulzerasib
Drug Alias Name福泽雷塞达伯特DupertGF-105IBI-351 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12C inhibitors
TargetsKRAS G12C
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2024/08/20
Country/TerritoryUnited StatesItalySpain +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenfleet Therapeutics (Shanghai) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesInnovent Biologics Technology LtdZhejiang Genfleet Therapeutics Co LtdGenfleet Therapeutics (Shanghai) Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A